Abstract
Holloway, Cameron J., Andrew J. Murray, Kay Mitchell, Daniel S. Martin, Andrew W. Johnson, Lowri E. Cochlin, Ion Codreanu, Sundeep Dhillon, George W. Rodway, Tom Ashmore, Denny Z.H. Levett, Stefan Neubauer, Hugh E. Montgomery, Michael P.W. Grocott, and Kieran Clarke, on behalf of the Caudwell Xtreme Everest 2009 Investigators. Oral Coenzyme Q supplementation does not prevent cardiac alterations during a high altitude trek to Everest Base Camp. High Alt Med Biol 15:000 - 000, 2014. - Exposure to high altitude is associated with sustained, but reversible, changes in cardiac mass, diastolic function, and high-energy phosphate metabolism. Whilst the underlying mechanisms remain elusive, tissue hypoxia increases generation of reactive oxygen species (ROS), which can stabilize hypoxia-inducible factor (HIF) transcription factors, bringing about transcriptional changes that suppress oxidative phosphorylation and activate autophagy. We therefore investigated whether oral supplementation with an antioxidant, Coenzyme Q10, prevented the cardiac perturbations associated with altitude exposure. Twenty-three volunteers (10 male, 13 female, 46±3 years) were recruited from the 2009 Caudwell Xtreme Everest Research Treks and studied before, and within 48 h of return from, a 17-day trek to Everest Base Camp, with subjects receiving either no intervention (controls) or 300 mg Coenzyme Q10 per day throughout altitude exposure. Cardiac magnetic resonance imaging and echocardiography were used to assess cardiac morphology and function. Following altitude exposure, body mass fell by 3 kg in all subjects (p<0.001), associated with a loss of body fat and a fall in BMI. Post-trek, left ventricular mass had decreased by 11% in controls (p<0.05) and by 16% in Coenzyme Q10-treated subjects (p<0.001), whereas mitral inflow E/A had decreased by 18% in controls (p<0.05) and by 21% in Coenzyme Q10-treated subjects (p<0.05). Coenzyme Q10 supplementation did not, therefore, prevent the loss of left ventricular mass or change in diastolic function that occurred following a trek to Everest Base Camp.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 459-467 |
| Number of pages | 9 |
| Journal | High Altitude Medicine and Biology |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 1 2014 |
| Externally published | Yes |
Fingerprint
Keywords
- altitude
- cardiac metabolism
- Coenzyme Q10
- heart function
- hypoxia
ASJC Scopus subject areas
- Medicine(all)
- Physiology
- Public Health, Environmental and Occupational Health
Cite this
Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp. / Holloway, Cameron J.; Murray, Andrew J.; Mitchell, Kay; Martin, Daniel S.; Johnson, Andrew W.; Cochlin, Lowri E.; Codreanu, Ion; Dhillon, Sundeep; Rodway, George W; Ashmore, Tom; Levett, Denny Z H; Neubauer, Stefan; Montgomery, Hugh E.; Grocott, Michael P W; Clarke, Kieran.
In: High Altitude Medicine and Biology, Vol. 15, No. 4, 01.12.2014, p. 459-467.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp
AU - Holloway, Cameron J.
AU - Murray, Andrew J.
AU - Mitchell, Kay
AU - Martin, Daniel S.
AU - Johnson, Andrew W.
AU - Cochlin, Lowri E.
AU - Codreanu, Ion
AU - Dhillon, Sundeep
AU - Rodway, George W
AU - Ashmore, Tom
AU - Levett, Denny Z H
AU - Neubauer, Stefan
AU - Montgomery, Hugh E.
AU - Grocott, Michael P W
AU - Clarke, Kieran
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Holloway, Cameron J., Andrew J. Murray, Kay Mitchell, Daniel S. Martin, Andrew W. Johnson, Lowri E. Cochlin, Ion Codreanu, Sundeep Dhillon, George W. Rodway, Tom Ashmore, Denny Z.H. Levett, Stefan Neubauer, Hugh E. Montgomery, Michael P.W. Grocott, and Kieran Clarke, on behalf of the Caudwell Xtreme Everest 2009 Investigators. Oral Coenzyme Q supplementation does not prevent cardiac alterations during a high altitude trek to Everest Base Camp. High Alt Med Biol 15:000 - 000, 2014. - Exposure to high altitude is associated with sustained, but reversible, changes in cardiac mass, diastolic function, and high-energy phosphate metabolism. Whilst the underlying mechanisms remain elusive, tissue hypoxia increases generation of reactive oxygen species (ROS), which can stabilize hypoxia-inducible factor (HIF) transcription factors, bringing about transcriptional changes that suppress oxidative phosphorylation and activate autophagy. We therefore investigated whether oral supplementation with an antioxidant, Coenzyme Q10, prevented the cardiac perturbations associated with altitude exposure. Twenty-three volunteers (10 male, 13 female, 46±3 years) were recruited from the 2009 Caudwell Xtreme Everest Research Treks and studied before, and within 48 h of return from, a 17-day trek to Everest Base Camp, with subjects receiving either no intervention (controls) or 300 mg Coenzyme Q10 per day throughout altitude exposure. Cardiac magnetic resonance imaging and echocardiography were used to assess cardiac morphology and function. Following altitude exposure, body mass fell by 3 kg in all subjects (p<0.001), associated with a loss of body fat and a fall in BMI. Post-trek, left ventricular mass had decreased by 11% in controls (p<0.05) and by 16% in Coenzyme Q10-treated subjects (p<0.001), whereas mitral inflow E/A had decreased by 18% in controls (p<0.05) and by 21% in Coenzyme Q10-treated subjects (p<0.05). Coenzyme Q10 supplementation did not, therefore, prevent the loss of left ventricular mass or change in diastolic function that occurred following a trek to Everest Base Camp.
AB - Holloway, Cameron J., Andrew J. Murray, Kay Mitchell, Daniel S. Martin, Andrew W. Johnson, Lowri E. Cochlin, Ion Codreanu, Sundeep Dhillon, George W. Rodway, Tom Ashmore, Denny Z.H. Levett, Stefan Neubauer, Hugh E. Montgomery, Michael P.W. Grocott, and Kieran Clarke, on behalf of the Caudwell Xtreme Everest 2009 Investigators. Oral Coenzyme Q supplementation does not prevent cardiac alterations during a high altitude trek to Everest Base Camp. High Alt Med Biol 15:000 - 000, 2014. - Exposure to high altitude is associated with sustained, but reversible, changes in cardiac mass, diastolic function, and high-energy phosphate metabolism. Whilst the underlying mechanisms remain elusive, tissue hypoxia increases generation of reactive oxygen species (ROS), which can stabilize hypoxia-inducible factor (HIF) transcription factors, bringing about transcriptional changes that suppress oxidative phosphorylation and activate autophagy. We therefore investigated whether oral supplementation with an antioxidant, Coenzyme Q10, prevented the cardiac perturbations associated with altitude exposure. Twenty-three volunteers (10 male, 13 female, 46±3 years) were recruited from the 2009 Caudwell Xtreme Everest Research Treks and studied before, and within 48 h of return from, a 17-day trek to Everest Base Camp, with subjects receiving either no intervention (controls) or 300 mg Coenzyme Q10 per day throughout altitude exposure. Cardiac magnetic resonance imaging and echocardiography were used to assess cardiac morphology and function. Following altitude exposure, body mass fell by 3 kg in all subjects (p<0.001), associated with a loss of body fat and a fall in BMI. Post-trek, left ventricular mass had decreased by 11% in controls (p<0.05) and by 16% in Coenzyme Q10-treated subjects (p<0.001), whereas mitral inflow E/A had decreased by 18% in controls (p<0.05) and by 21% in Coenzyme Q10-treated subjects (p<0.05). Coenzyme Q10 supplementation did not, therefore, prevent the loss of left ventricular mass or change in diastolic function that occurred following a trek to Everest Base Camp.
KW - altitude
KW - cardiac metabolism
KW - Coenzyme Q10
KW - heart function
KW - hypoxia
UR - http://www.scopus.com/inward/record.url?scp=84919694407&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919694407&partnerID=8YFLogxK
U2 - 10.1089/ham.2013.1053
DO - 10.1089/ham.2013.1053
M3 - Article
C2 - 24661196
AN - SCOPUS:84919694407
VL - 15
SP - 459
EP - 467
JO - High Altitude Medicine and Biology
JF - High Altitude Medicine and Biology
SN - 1527-0297
IS - 4
ER -